Cargando…

Correction to: Development of a novel TLR8 agonist for cancer immunotherapy

Detalles Bibliográficos
Autores principales:	Wang, Yuxun, Yang, Heping, Li, Huanping, Zhao, Shuda, Zeng, Yikun, Zhang, Panpan, Lin, Xiaoqin, Sun, Xiaoxiang, Wang, Longsheng, Fu, Guangliang, Gao, Yaqiao, Wang, Pei, Gao, Daxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607363/ https://www.ncbi.nlm.nih.gov/pubmed/35006462 http://dx.doi.org/10.1186/s43556-021-00042-3

Ejemplares similares

Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2020)

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
por: Smirnov, DV, et al.
Publicado: (2013)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy
por: Rodell, Christopher B., et al.
Publicado: (2019)

Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
por: Michaelis, Katherine A., et al.
Publicado: (2019)

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
por: Frega, Giorgio, et al.
Publicado: (2020)

Molecular dynamics simulations reveal the selectivity mechanism of structurally similar agonists to TLR7 and TLR8
por: Wang, Xiaoyu, et al.
Publicado: (2022)

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
por: Rodell, Christopher B., et al.
Publicado: (2018)

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
por: Mullins, Stefanie R., et al.
Publicado: (2019)

The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma
por: Zhou, Zhimei, et al.
Publicado: (2021)

Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment
por: Smith, Anton A. A., et al.
Publicado: (2020)

Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity
por: Younes, Ahmed I., et al.
Publicado: (2020)

Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists
por: Cheng, Kui, et al.
Publicado: (2015)

Correction: Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Publicado: (2023)

STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation
por: Zhang, Bo-Dou, et al.
Publicado: (2022)

TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects
por: Lu, Hailing
Publicado: (2014)

Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma
por: Deng, Shuanglin, et al.
Publicado: (2014)

The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview
por: Veneziani, Irene, et al.
Publicado: (2022)

Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response
por: Zhang, Lele, et al.
Publicado: (2021)

IMMU-14. WAKING THE SLEEPING GIANT: TLR7/8 AGONIST TREATMENT STIMULATES TUMOR-ASSOCIATED MYELOID CELLS FOR MEDULLOBLASTOMA IMMUNOTHERAPY
por: Pauneto, Coral Alicea, et al.
Publicado: (2023)

TLR4 Agonist and Hypoxia Synergistically Promote the Formation of TLR4/NF-κB/HIF-1α Loop in Human Epithelial Ovarian Cancer
por: Zhao, Bin, et al.
Publicado: (2022)

Correction: Induction of TLR-2 and TLR-5 Expression by Helicobacter pylori Switches cagPAI-Dependent Signalling Leading to the Secretion of IL-8 and TNF-α
por: Kumar Pachathundikandi, Suneesh, et al.
Publicado: (2015)

Correction: Toll-Like Receptor (TLR) 2 and TLR4 Differentially Regulate Doxorubicin Induced Cardiomyopathy in Mice
por: Ma, Yonggang, et al.
Publicado: (2012)

Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib
por: Gao, Ningning, et al.
Publicado: (2016)

Correction: Correction: Induction of TLR-2 and TLR-5 Expression by Helicobacter pylori Switches cagPAI-Dependent Signalling Leading to the Secretion of IL-8 and TNF-α
Publicado: (2015)

TLR7 agonist induced repression of hepatocellular carcinoma via the TLR7-IKK-NF-κB-IL6 signaling pathway
por: REN, XINGBIN, et al.
Publicado: (2016)

Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano‐Immunoadjuvant
por: Wei, Jingjing, et al.
Publicado: (2022)

Stimulation of Innate Immune Cells by Light-Activated TLR7/8 Agonists
por: Ryu, Keun Ah, et al.
Publicado: (2014)

Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists
por: Alharbi, Arwaf S, et al.
Publicado: (2020)

Tumor-targeted delivery of a STING agonist improves cancer immunotherapy
por: Wu, You-tong, et al.
Publicado: (2022)

Synergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model
por: Gao, Dong, et al.
Publicado: (2017)

Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity
por: Dietsch, Gregory N., et al.
Publicado: (2016)

Route of Administration of the TLR9 Agonist CpG Critically Determines the Efficacy of Cancer Immunotherapy in Mice
por: Nierkens, Stefan, et al.
Publicado: (2009)

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy
por: Kapp, Kerstin, et al.
Publicado: (2019)

Correction: Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy
por: Shi, Chen, et al.
Publicado: (2023)

Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity
por: Beesu, Mallesh, et al.
Publicado: (2015)

ProLonged Liposomal Delivery of TLR7/8 Agonist for Enhanced Cancer Vaccine
por: Kim, Sehui, et al.
Publicado: (2023)

Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer
por: Chang, Rui, et al.
Publicado: (2023)

Deoxyguanosine is a TLR7 agonist
por: Davenne, Tamara, et al.
Publicado: (2019)

Pharmacological Activation of p53 during Human Monocyte to Macrophage Differentiation Attenuates Their Pro-Inflammatory Activation by TLR4, TLR7 and TLR8 Agonists
por: Namgaladze, Dmitry, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8ondf1s4kfj79o4k1btq4ilkv1